Ted W. Johnson

5.4k total citations
28 papers, 1.6k citations indexed

About

Ted W. Johnson is a scholar working on Molecular Biology, Organic Chemistry and Surgery. According to data from OpenAlex, Ted W. Johnson has authored 28 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 7 papers in Organic Chemistry and 6 papers in Surgery. Recurrent topics in Ted W. Johnson's work include Lung Cancer Treatments and Mutations (6 papers), Cancer therapeutics and mechanisms (5 papers) and Pancreatic function and diabetes (4 papers). Ted W. Johnson is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Cancer therapeutics and mechanisms (5 papers) and Pancreatic function and diabetes (4 papers). Ted W. Johnson collaborates with scholars based in United States, Sweden and Switzerland. Ted W. Johnson's co-authors include Martin P. Edwards, Marc Montminy, Klaus Dress, Rebecca A. Gallego, Bernard Peers, James Leonard, Kevin Ferreri, Sang Yeoup Lee, Michael E. Jung and E. J. Corey and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Angewandte Chemie International Edition.

In The Last Decade

Ted W. Johnson

28 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ted W. Johnson United States 18 790 456 395 331 214 28 1.6k
Kevin P. Madauss United States 19 783 1.0× 151 0.3× 162 0.4× 575 1.7× 161 0.8× 28 1.6k
Jay Wrobel United States 33 876 1.1× 289 0.6× 1.5k 3.7× 399 1.2× 96 0.4× 76 2.8k
Frédéric Massé Canada 18 749 0.9× 281 0.6× 361 0.9× 135 0.4× 54 0.3× 22 1.4k
Ursula Müller‐Vieira Germany 24 454 0.6× 158 0.3× 225 0.6× 292 0.9× 105 0.5× 29 1.5k
Mathias Färnegårdh Sweden 13 531 0.7× 153 0.3× 105 0.3× 378 1.1× 90 0.4× 14 1.1k
Toshimasa Tanaka Japan 27 1.3k 1.6× 183 0.4× 992 2.5× 110 0.3× 327 1.5× 59 2.6k
Jon Read United Kingdom 25 1.3k 1.7× 156 0.3× 369 0.9× 60 0.2× 227 1.1× 40 2.1k
R.J. Skene United States 22 1.4k 1.7× 159 0.3× 485 1.2× 123 0.4× 209 1.0× 34 2.5k
Robert J. Ife United Kingdom 23 865 1.1× 432 0.9× 417 1.1× 53 0.2× 83 0.4× 52 1.7k
Atsushi Kittaka Japan 28 854 1.1× 86 0.2× 709 1.8× 878 2.7× 109 0.5× 186 2.6k

Countries citing papers authored by Ted W. Johnson

Since Specialization
Citations

This map shows the geographic impact of Ted W. Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ted W. Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ted W. Johnson more than expected).

Fields of papers citing papers by Ted W. Johnson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ted W. Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ted W. Johnson. The network helps show where Ted W. Johnson may publish in the future.

Co-authorship network of co-authors of Ted W. Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of Ted W. Johnson. A scholar is included among the top collaborators of Ted W. Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ted W. Johnson. Ted W. Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Johnson, Ted W., Jochen K. Lennerz, Charlotte Lee, et al.. (2020). Resistance to lorlatinib in ROS1 fusion-positive non-small cell lung cancer.. Journal of Clinical Oncology. 38(15_suppl). 9611–9611. 16 indexed citations
2.
Johnson, Eric F., Michele McTigue, Rebecca A. Gallego, et al.. (2019). Multiple conformational states of the HPK1 kinase domain in complex with sunitinib reveal the structural changes accompanying HPK1 trans-regulation. Journal of Biological Chemistry. 294(23). 9029–9036. 21 indexed citations
3.
Johnson, Ted W., Rebecca A. Gallego, & Martin P. Edwards. (2018). Lipophilic Efficiency as an Important Metric in Drug Design. Journal of Medicinal Chemistry. 61(15). 6401–6420. 224 indexed citations
4.
Johnson, Ted W., Ben Bolaños, Alexei Brooun, et al.. (2018). Reviving B-Factors: Activating ALK Mutations Increase Protein Dynamics of the Unphosphorylated Kinase. ACS Medicinal Chemistry Letters. 9(9). 872–877. 6 indexed citations
5.
6.
Gajiwala, K.S., Neil B. Grodsky, Ben Bolaños, et al.. (2017). The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase. Journal of Biological Chemistry. 292(38). 15705–15716. 41 indexed citations
7.
Guan, Jikui, Elizabeth R. Tucker, Haisu Wan, et al.. (2016). The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN. Disease Models & Mechanisms. 9(9). 941–952. 53 indexed citations
8.
Elleraas, Jeff, Jason Ewanicki, Ted W. Johnson, et al.. (2016). Conformational Studies and Atropisomerism Kinetics of the ALK Clinical Candidate Lorlatinib (PF‐06463922) and Desmethyl Congeners. Angewandte Chemie. 128(11). 3654–3659. 7 indexed citations
9.
Levin, Victor A., Peter J. Tonge, James M. Gallo, et al.. (2015). CNS Anticancer Drug Discovery and Development Conference White Paper. Neuro-Oncology. 17(suppl 6). vi1–vi26. 34 indexed citations
10.
Johnson, Ted W., et al.. (2015). Recovery and Stability of Δ9-Tetrahydrocannabinol Using the Oral-Eze®Oral Fluid Collection System and Intercept®Oral Specimen Collection Device. Journal of Analytical Toxicology. 39(8). 648–654. 4 indexed citations
11.
Burke, Benjamin J., Ted W. Johnson, Sacha Ninkovic, et al.. (2015). Effect of water solvation on the lipophilicity of isomeric pyrimidine-carboxamides. Bioorganic & Medicinal Chemistry. 23(13). 3408–3413. 5 indexed citations
12.
13.
Johnson, Ted W., Klaus Dress, & Martin P. Edwards. (2009). Using the Golden Triangle to optimize clearance and oral absorption. Bioorganic & Medicinal Chemistry Letters. 19(19). 5560–5564. 266 indexed citations
14.
Jung, Michael E. & Ted W. Johnson. (2001). First total synthesis of xestobergsterol A and active structural analogues of the xestobergsterols. Tetrahedron. 57(8). 1449–1481. 29 indexed citations
15.
16.
Lazerwith, Scott E., Ted W. Johnson, & E. J. Corey. (2000). Syntheses and Stereochemical Revision of Pseudopterosin G−J Aglycon and Helioporin E. Organic Letters. 2(15). 2389–2392. 43 indexed citations
17.
Jung, Michael E. & Ted W. Johnson. (1999). Unusual Cyclization Products Derived from Photolysis of Breslow's Steroidal Benzophenone Esters. The Journal of Organic Chemistry. 64(20). 7651–7653. 5 indexed citations
18.
Jung, Michael E. & Ted W. Johnson. (1997). Synthesis of 7-Deoxyxestobergsterol A, a Novel Pentacyclic Steroid of the Xestobergsterol Class1. Journal of the American Chemical Society. 119(50). 12412–12413. 21 indexed citations
19.
Sharma, Surangama, Ulupi S. Jhala, Ted W. Johnson, et al.. (1997). Hormonal Regulation of an Islet-Specific Enhancer in the Pancreatic Homeobox Gene STF-1. Molecular and Cellular Biology. 17(5). 2598–2604. 96 indexed citations
20.
Peers, Bernard, Seema Sharma, Ted W. Johnson, Mark P. Kamps, & Marc Montminy. (1995). The Pancreatic Islet Factor STF-1 Binds Cooperatively with Pbx to a Regulatory Element in the Somatostatin Promoter: Importance of the FPWMK Motif and of the Homeodomain. Molecular and Cellular Biology. 15(12). 7091–7097. 135 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kevin P. Madauss Breakdown of academic impact, for papers by Jay Wrobel Breakdown of academic impact, for papers by Frédéric Massé Breakdown of academic impact, for papers by Ursula Müller‐Vieira Breakdown of academic impact, for papers by Mathias Färnegårdh Breakdown of academic impact, for papers by Toshimasa Tanaka Breakdown of academic impact, for papers by Jon Read Breakdown of academic impact, for papers by R.J. Skene Breakdown of academic impact, for papers by Robert J. Ife Breakdown of academic impact, for papers by Atsushi Kittaka
Rankless by CCL
2026